CXCR4 and Stroke: Recently, several studies reported that systemic treatment with AMD3100, a highly selective CXCR4 antagonist, significantly improved the functional outcome following experimental stroke through attenuating the inflammatory response and microglial activation (Huang et al., 2013; Ruscher et al., 2013; Walter et al., 2015).